Artmış Kalıntı Kolesterol Kan Düzeyleri İlk Defa Geçirilen Akut Koroner Sendrom ile İlişkilidir

Abstract

Giriş: Açlık dışı kalıntı kolesterolün artması, artmış düşük dansiteli lipoprotein kolesterol (LDL-C) gibi iskemik kardiyovasküler hastalıklar için artmış risk ile ilişkilidir. Çalışmamızın amacı, ilk kez akut koroner sendrom (AKS) ile gelen hastalarda kalıntı kolesterol ve akut koroner sendromun arasındaki ilişkiyi araştırmaktır.

Hastalar ve Yöntem: İlk kez akut koroner sendrom ile başvuran 226 hasta ve normal koroner arter olarak sonuçlanmış 192 elektif koroner anjiyografi hastasında, diğer lipit profili parametrelerinin yanı sıra, açlık dışı kalıntı kolesterolün artan konsantrasyonlarını karşılaştırdık.

Bulgular: AKS hastaları kontrol grubu ile karşılaştırıldığında erkek cinsiyet fazla, daha genç ve daha fazla oranda diabetes mellitus mevcuttu (tümü için p< 0.001). AKS hastalarında glukoz ve beyaz kan hücresi düzeyleri de daha yüksekti. Kalıntı kolesterol, LDL-C değerine benzer şekilde, AKS grubunda istatistiksel olarak kontrol grubu ile karşılaştırıldığında daha yüksekti (p< 0.001). Tek değişkenli ve çok değişkenli ikili lojistik regresyon analizinde yüksek kan kalıntı kolesterolü, yüksek kan LDL-C değerleri ve düşük kan HDL-C değerleri ile akut koroner sendromlar arasında anlamlı bir ilişki mevcuttu.

Sonuç: Çalışmamız, yüksek kan LDL-C seviyelerinde olduğu gibi artmış kalıntı kolesterol düzeylerinin artmış ilk kez yaşanılan AKS riski ile ilişkili olduğunu göstermiştir. AKS hastalarında LDL-C düzeylerinin düşürülmesinin yanı sıra kalıntı kolesterol düzeylerinin düşürülmesi üzerine daha fazla çalışma yapılmalı ve odaklanılmalıdır.

Keywords

• Akut koroner sendrom,kalıntı kolesterol,trigliseritten zengin lipoproteinler

Increased Remnant Cholesterol Blood Concentration Associated with First Acute Coronary Syndrome

Abstract

Introduction: This study aimed to investigate the association between remnant cholesterol and acute coronary syndrome (ACS) and its predictive value for acute coronary syndrome occurring for the first time.

Patients and Methods: We compared increasing concentrations of non-fasting remnant cholesterol aside from other lipid profile parameters to investigate this association in 226 patients with ACS for the first time and 192 elective coronary angiography patients with normal coronary arteries.

Results: Patients with ACS were mostly males and were younger than those in the control group; moreover, they had higher percentage of diabetes mellitus (for all p< 0.001). Glucose and white blood cell levels at admission were also higher in patients with ACS. Remnant cholesterol level (such as LDL-C) was statistically higher in the ACS group compared with those of the control group (p< 0.001). In the univariate and bivariate binary logistic regression analysis, high blood remnant cholesterol, high blood LDL-C, and low blood HDL-C levels had a predictive value for ACSs. Conclusion: This study demonstrated that remnant cholesterol levels (such as high blood LDL-C levels) are associated with increased risk of ACS for the first time. Further studies should be performed focusing on lowering remnant cholesterol levels apart from lowering LDL-C levels in patients with ACS.

Keywords

• Acute coronary syndrome,remnant cholesterol,triglyceride-rich lipoproteins

References

1. 1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. ESC Scientific Document Group. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999-3058.
2. 2. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of ApoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009;29:424-30.
3. 3. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol 2004;44:720-32.
4. 4. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol 2000;11:615-20.
5. 5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. 6. Miller M, Ginsberg HN, Schaefer E J. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008;101:1003-8.
7. 7. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-36.
8. 8. Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.

9. 9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
10. 10. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384:626-35.
11. 11. Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther 2014;141:358-67.
12. 12. Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, Lumley JS, La Ville AE, et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991;11:569-77.
13. 13. Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb 1992;12:6-18.
14. 14. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb 1995;15:534-42.
15. 15. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116:1832-44.
16. 16. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333.
17. 17. Jepsen AMK, Langsted A, Varbo A, Bang LE, Kamstrup PR, Nordestgaard B. Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease. Clin Chem 2016;62:593-604.
18. 18. Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Part B):2889-934.
19. 19. Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al. European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014;2:655-66.
20. 20. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61.
21. 21. Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, while elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013;128:1298-309.